100 Most Influential People in Healthcare – 2016

• Compensation: NA
• Years on list: 1

Perhaps no single sector of the economy wears a bigger bull's-eye than Big Pharma. But Ubl seemingly never tires of making the case that pharmaceutical companies are among the leaders in spending on research and development ($51 billion in 2014) and need a return on investment if they are to keep life-saving drugs in the pipeline. Ubl succeeded John Castellani last year after serving as CEO of the Advanced Medical Technology Association, where he pushed Medicare to reimburse for medical technologies and asking the Ford and Drug Administration to streamline product review processes. He also is credited with helping delay implementation of a medical-device tax as part of the Affordable Care Act.